RT Journal Article
SR Electronic
T1 Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2000547
DO 10.1183/13993003.00547-2020
VO 55
IS 5
A1 Guan, Wei-jie
A1 Liang, Wen-hua
A1 Zhao, Yi
A1 Liang, Heng-rui
A1 Chen, Zi-sheng
A1 Li, Yi-min
A1 Liu, Xiao-qing
A1 Chen, Ru-chong
A1 Tang, Chun-li
A1 Wang, Tao
A1 Ou, Chun-quan
A1 Li, Li
A1 Chen, Ping-yan
A1 Sang, Ling
A1 Wang, Wei
A1 Li, Jian-fu
A1 Li, Cai-chen
A1 Ou, Li-min
A1 Cheng, Bo
A1 Xiong, Shan
A1 Ni, Zheng-yi
A1 Xiang, Jie
A1 Hu, Yu
A1 Liu, Lei
A1 Shan, Hong
A1 Lei, Chun-liang
A1 Peng, Yi-xiang
A1 Wei, Li
A1 Liu, Yong
A1 Hu, Ya-hua
A1 Peng, Peng
A1 Wang, Jian-ming
A1 Liu, Ji-yang
A1 Chen, Zhong
A1 Li, Gang
A1 Zheng, Zhi-jian
A1 Qiu, Shao-qin
A1 Luo, Jie
A1 Ye, Chang-jiang
A1 Zhu, Shao-yong
A1 Cheng, Lin-ling
A1 Ye, Feng
A1 Li, Shi-yue
A1 Zheng, Jin-ping
A1 Zhang, Nuo-fu
A1 Zhong, Nan-shan
A1 He, Jian-xing
A1 ,
YR 2020
UL http://erj.ersjournals.com/content/55/5/2000547.abstract
AB Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.Objective To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.Methods We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.Results The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5